Integer Holdings Corporation Class Action Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: Globenewswire
- Sales Guidance Cut: On October 23, 2025, Integer lowered its full-year sales guidance to between $1.840 billion and $1.854 billion, below expectations, forecasting net sales growth of -2% to 2% for 2026, which significantly undermines investor confidence.
- Decline in New Product Sales: During the earnings call, management revealed that sales of three new products, including two electrophysiology devices, are expected to decline in 2026 due to slower market adoption, further impacting overall performance.
- Stock Price Plummet: Following the sales guidance cut, Integer's stock price fell by $35.22, or 32.3%, closing at $73.89 on October 23, 2025, resulting in substantial losses for investors.
- Class Action Initiated: Investors who purchased Integer stock between July 25, 2024, and October 22, 2025, and suffered losses can file to become lead plaintiffs in a class action lawsuit by February 9, 2026, alleging significant misstatements regarding sales and market prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ITGR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 93.38 USD with a low forecast of 75.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 86.470
Low
75.00
Averages
93.38
High
140.00
Current: 86.470
Low
75.00
Averages
93.38
High
140.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Integer Holdings Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Integer Holdings (NYSE: ITGR) common stock between July 25, 2024, and October 22, 2025, to apply as lead plaintiffs by February 9, 2026, to protect their rights in the ongoing class action lawsuit.
- Fee Structure: Investors joining the class action will incur no out-of-pocket expenses, as attorney fees will be covered through a contingency fee arrangement, thereby lowering the financial barrier for participation and enabling more investors to seek compensation.
- Lawsuit Context: The lawsuit alleges that Integer materially overstated its competitive position in the electrophysiology manufacturing market and misrepresented customer demand visibility, resulting in investor losses when the truth emerged, highlighting significant corporate misconduct.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having achieved the largest settlement against a Chinese company and consistently ranking among the top firms for securities class action settlements, underscoring its expertise and effectiveness in handling such cases.
Continue Reading
Integer Holdings Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by February 9, 2026, to participate in the securities class action against Integer Holdings, which involves stock purchases from July 25, 2024, to October 22, 2025, highlighting investor concerns over the company's disclosure practices.
- Earnings Warning Impact: On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, significantly below analyst expectations, resulting in a more than 32% drop in share price from $109.11 to $73.89 in a single day, reflecting market disappointment with the company's performance.
- Legal Liability Allegations: The lawsuit alleges that Integer and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to significant legal and financial risks, impacting its future market performance.
- Investor Rights Protection: KSF law firm reminds investors that those who purchased Integer shares during the class period may have the right to seek compensation for economic losses through legal channels, emphasizing the importance of investor rights in corporate governance.
Continue Reading